11:06 AM EST, 11/13/2024 (MT Newswires) -- Lexaria Bioscience ( LEXX ) said Wednesday it received approval from the lead clinical site's human research ethics committee to begin dosing in its phase 1b, 12-week chronic study of GLP-1-H24-4 for diabetes and weight loss.

The study will feature five arms testing various DehydraTECH formulations including CBD capsules, semaglutide capsules, semaglutide combined with CBD capsules, Rybelsus tablets as control, and optional tirzepatide capsules, the company said.

Clinical test article manufacturing for all study arms is complete, with a first patient, first dose study milestone slated to be achieved in late December or January 2025, Lexaria said.

The study will take place across seven clinical sites in Australia and is expected to be recognized by the US Food and Drug Administration as a registrational phase 1b study, the company said.

Shares of Lexaria were up 3.9% in recent Wednesday trading.

Price: 2.39, Change: +0.09, Percent Change: +3.91